89bio 관리

관리 기준 확인 2/4

89bio CEO는 Rohan Palekar, Jul2018 에 임명되었습니다 의 임기는 6.33 년입니다. 총 연간 보상은 $ 5.59M, 10.9% 로 구성됩니다. 10.9% 급여 및 89.1% 보너스(회사 주식 및 옵션 포함). 는 $ 2.55M 가치에 해당하는 회사 주식의 0.24% 직접 소유합니다. 2.55M. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 4.3 년입니다.

주요 정보

Rohan Palekar

최고 경영자

US$5.6m

총 보상

CEO 급여 비율	10.9%
CEO 임기	6.3yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	4.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Rohan Palekar 의 보수는 89bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$289m
Jun 30 2024	n/a	n/a	-US$175m
Mar 31 2024	n/a	n/a	-US$165m
Dec 31 2023	US$6m	US$611k	-US$142m
Sep 30 2023	n/a	n/a	-US$127m
Jun 30 2023	n/a	n/a	-US$119m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$3m	US$588k	-US$102m
Sep 30 2022	n/a	n/a	-US$104m
Jun 30 2022	n/a	n/a	-US$105m
Mar 31 2022	n/a	n/a	-US$101m
Dec 31 2021	US$5m	US$565k	-US$90m
Sep 30 2021	n/a	n/a	-US$76m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$5m	US$530k	-US$49m
Sep 30 2020	n/a	n/a	-US$56m
Jun 30 2020	n/a	n/a	-US$60m
Mar 31 2020	n/a	n/a	-US$64m
Dec 31 2019	US$1m	US$431k	-US$57m
Sep 30 2019	n/a	n/a	-US$44m
Jun 30 2019	n/a	n/a	-US$30m
Dec 31 2018	US$708k	US$195k	-US$18m

보상 대 시장: Rohan 의 총 보상 ($USD 5.59M )은 US 시장( $USD 3.15M ).

보상과 수익: 회사가 수익성이 없는 동안 Rohan 의 보상이 증가했습니다.

CEO

Rohan Palekar (58 yo)

6.3yrs

테뉴어

US$5,587,661

보상

Mr. Rohan Palekar serves as the Chief Executive Officer and Director at 89bio, Inc. since July 16, 2018. He is an Independent Director at Neoleukin Therapeutics, Inc since March 02, 2022 and Neurogene Inc....

리더십 팀

이름	위치	테뉴어	보상	소유권
Rohan Palekar	CEO & Director	6.3yrs	US$5.59m	0.24% $ 2.6m
Quoc Le-Nguyen	Chief Technical Officer	5.7yrs	US$2.51m	0.11% $ 1.2m
Harry Mansbach	Chief Medical Officer	5.9yrs	US$2.54m	0.080% $ 837.8k
Ryan Martins	Chief Financial Officer	5.3yrs	데이터 없음	0.038% $ 401.6k
Francis Sarena	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Shiva Natarajan	Senior Vice President of Finance & Principal Accounting Officer	no data	데이터 없음	데이터 없음
Annie Chang	VP of Investor Relations & Corporate Communications	less than a year	데이터 없음	데이터 없음
Amanda Kurihara	Vice President of People & Culture	3.8yrs	데이터 없음	데이터 없음
Melissa Abel	Senior Vice President of Commercial Strategy	no data	데이터 없음	데이터 없음
Paul Shin	Senior Vice President of R&D Operations	2.8yrs	데이터 없음	데이터 없음
Michael Baldwin	Senior VP & Head of Quality	1.8yrs	데이터 없음	데이터 없음
Teresa Perney	Chief Regulatory & Quality Officer	less than a year	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: ETNB 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Rohan Palekar	CEO & Director	6.3yrs	US$5.59m	0.24% $ 2.6m
Kathleen LaPorte	Independent Director	3yrs	US$360.17k	0% $ 0
Lota Zoth	Independent Director	4.3yrs	US$363.33k	0% $ 0
Michael Hayden	Independent Director	6.6yrs	US$358.33k	0.21% $ 2.2m
Martin Babler	Independent Director	less than a year	데이터 없음	데이터 없음
Steven Altschuler Buser	Independent Chairman of the Board	4.7yrs	US$385.83k	0% $ 0
Charles McWherter	Director	less than a year	데이터 없음	데이터 없음
Edward Atkinson	Independent Director	2.8yrs	US$354.60k	0% $ 0
Derek DiRocco	Independent Director	6.6yrs	US$352.33k	0% $ 0

4.3yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: ETNB 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

89bio 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

CEO & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Recent updates

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $124.996747 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

89bio: Surviving A Competitive Space - For Now

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis

Price target decreased by 9.4% to US$33.44

New minor risk - Share price stability

Price target increased by 7.8% to US$37.44

89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.01 loss

Chief Financial Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Price target increased by 34% to US$33.75

Independent Director exercised options and sold US$92k worth of stock

Chief Financial Officer notifies of intention to sell stock

Price target increased to US$24.63

89bio, Inc. Announces Publication of Results of Phase 1B/2A Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & Hepatology

Consensus forecasts updated

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting(R) 2022

89bio Still Has A Chance As NASH Race Heats Up

Consensus forecasts updated

CEO & Director exercised options to buy US$478k worth of stock.

89bio, Inc. Presents Positive Results from Entrigue Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia At European Society of Cardiology Congress 2022

89Bio, Inc. Completes Enrollment in Enliven, the Phase 2B Trial of Pegozafermin for the Treatment of NASH

89bio completes enrollment in phase 2 trial for NASH treatment

89Bio rallies on Deep Track Capital disclosing 10% stake

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Index

Price target decreased to US$45.67

89bio, Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$45.67

89bio, Inc. Appoints Edward Morrow Atkinson to the Board

CEO & Director recently bought US$53k worth of stock

89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 20 Patients in the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$102k worth of stock

COO & Chief Business Officer exercised options and sold US$109k worth of stock

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$114k worth of stock

Independent Director Anat Naschitz has left the company

89Bio Completes Target Enrollment in Histology Cohort to Evaluate Bio89-100 for the Treatment of Nash

Price target decreased to US$52.50

89bio: Undervalued Contender In Race For First NASH Drug Approval

COO & Chief Business Officer exercised options and sold US$104k worth of stock

CEO & Director recently bought US$118k worth of stock

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

COO & Chief Business Officer exercised options and sold US$124k worth of stock

89Bio Initiates Phase 2B Enliven Trial of Bio89-100 for the Treatment of Nash